Illumina Misses Revenue Forecast Causing Collateral Damage To Biotechs

Illumina shares crashed 25% to $139, after a warning on third quarter sales. The global leader in DNA sequencing systems warned that revenues missed forecast and would be $607M, well short of earlier guidance of $625-$630M.